Sunday 01 October 2023 - 14:47
In Business 43 Years - Since 1980
NOTE: our usual phone and fax lines are down, due to a dispute between our landlord and Verizon.
In the meantime, please use this mobile phone number: 978-715-9327 and this fax number:
The 25% Discount for Shopping Cart Purchases is now PERMANENT !!
For Online Shopping Cart Orders Only
In-Stock Sizes Only
See Check-out Page For Further Details
FREE SHIPPING TO THE U.S. AND 32 OTHER COUNTRIES! [Read more].
C-8999 Cabozantinib, S-Malate Salt, >99%
Synonyms : [XL-184]
Related Terms : [Cometriq]
- Size
- US $
- €
- £
- ¥
- 50 mg
- 53
- 50
- 43
- 7,900
- In stock
- 100 mg
- 66
- 62
- 54
- 9,900
- In stock
- 200 mg
- 105
- 99
- 86
- 15,700
- In stock
- 500 mg
- 223
- 210
- 182
- 33,300
- In stock
- 1 g
- 395
- 373
- 323
- 59,000
- In stock
- 2 g
- 634
- 599
- 519
- 94,700
- In stock
- 5 g
- 1,125
- 1,063
- 922
- 168,000
- In stock
- 10 g
- 1,760
- 1,663
- 1,443
- 262,900
- In stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
- M.W. 635.59
- C28H24FN3O5C4H6O5
- [1140909-48-3]
Solubility: Soluble in DMSO at 50 mg/mL; very poorly soluble in ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 2-4 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility.
- This research compound is the s-malate salt form of cabozantinib. Please see the free base form of cabozantinib, Cat. No. C-8901, Cabozantinib, Free Base, for further technical information.
- This cabozantinib product is the s-malate salt, whose CAS number is given above. The CAS number of the free base form is 849217-68-1.
- Another CAS number previously assigned to cabozantinib s-malate, namely 942407-59-2, has been deleted by CAS and is no longer in use.
- Cabozantinib S-Malate salt is the active ingredient in the drug product sold under the trade name Cabometyx® and Cometriq®. This drug is currently approved in at least one country for use in patients with progressive, metastatic medullary thyroid cancer. It is currently undergoing clinical trials for the treatment of prostate, ovarian, brain, melanoma, breast, non-small cell lung, pancreatic, hepatocellular and kidney cancers. NOTE: THE CABOZANTINIB SOLD BY LC LABORATORIES FOR RESEARCH IS NOT CABOMETYX® or COMETRIQ®, AND IS NOT FOR HUMAN USE.
- Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
- Not available in some countries; not available to some institutions; not available for some uses.
